NCT04791839View on ClinicalTrials.gov

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2029

Conditions
Non Small Cell Lung CancerNon-small Cell CarcinomaNon-small Cell Lung Cancer
Interventions
DRUG

Zimberelimab

Zimberelimab will be supplied by Arcus Biosciences.

DRUG

Domvanalimab

Domvanalimab will be supplied by Arcus Biosciences.

DRUG

Etrumadenant

Etrumadenant will be supplied by Arcus Biosciences.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Arcus Biosciences, Inc.
All Listed Sponsors
collaborator

Arcus Biosciences, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04791839 - Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter